Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant
chemotherapy in patients with locally differentiated digestive NEC. The recommended
chemotherapy is based on the current reference combination of platinum (cisplatin or
carboplatin) and etoposide (VP16). For anorectal locations, radiochemotherapy is proposed to
avoid the morbidity of conventional surgery.
The objective of the study is to improve relapse-free survival (RFS) in NEC patients treated
with neoadjuvant chemotherapy followed by surgery or chemoradiotherapy.
In parallel, we will perform a prospective cohort study with patients whose diagnosis is made
during surgery, who have not received neoadjuvant treatment, and who are offered an adjuvant
treatment of the same type (combination of platinum and platinum salts and etoposide).
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group